Related Experiment Video
Updated: Aug 15, 2025

Analysis of Tubular Membrane Networks in Cardiac Myocytes from Atria and Ventricles
Published on: October 15, 2014
Polycystin-1 Is a Crucial Regulator of BIN1 Expression and T-Tubule Remodeling Associated with the Development of
Magda C Díaz-Vesga1,2,3, Raúl Flores-Vergara1,2,4, Jaime A Riquelme4,5
1Programa de Fisiología y Biofísica, ICBM, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
Insights
Polycystin-1 (PC1) in heart cells is crucial for preventing dilated cardiomyopathy. Reduced PC1 impairs BIN1 expression and T-tubule structure, leading to heart failure in autosomal dominant polycystic kidney disease (ADPKD) models.
Area of Science:
- Cardiovascular Pathophysiology
- Molecular Cardiology
- Genetics of Kidney Disease
Background:
- Cardiomyopathy is frequent in autosomal dominant polycystic kidney disease (ADPKD) patients, irrespective of kidney function or blood pressure.
- The specific role of cardiomyocyte polycystin-1 (PC1) in cardiovascular disease is not well understood.
- PC1 influences BIN1, a protein vital for T-tubule structure, and its dysregulation can cause cardiac issues.
Purpose of the Study:
- To investigate the role of cardiomyocyte-specific PC1 in heart failure (HF) development.
- To explore the potential mechanism involving reduced BIN1 expression and T-tubule remodeling.
- To analyze the impact of PC1 deficiency on cardiac function and survival in a mouse model.
Main Methods:
- Utilized a cardiomyocyte-specific PC1-silenced (PC1-KO) mouse model.
- Assessed cardiac function using echocardiography.
- Quantified BIN1 mRNA, protein levels, and isoform expression.
- Examined T-tubule structure and plasma BIN1 levels.
Main Results:
- PC1-KO mice showed impaired cardiac function and developed dilated cardiomyopathy, with sudden death observed.
- Decreased total BIN1 expression and altered BIN1 isoform ratios were noted in PC1-KO mice.
- T-tubule remodeling correlated with reduced PC1-BIN1 expression and HF development.
Conclusions:
- Reduced PC1 expression in cardiomyocytes leads to dilated cardiomyopathy.
- Diminished BIN1 expression and T-tubule remodeling are key mechanisms in PC1-deficient cardiomyopathy.
- PC1's positive modulation of BIN1 offers a potential therapeutic target for ADPKD-related cardiomyopathy.
Abstract:
Cardiomyopathy is commonly observed in patients with autosomal dominant polycystic kidney disease (ADPKD), even when they have normal renal function and arterial pressure. The role of cardiomyocyte polycystin-1 (PC1) in cardiovascular pathophysiology remains unknown. PC1 is a potential regulator of BIN1 that maintains T-tubule structure, and alterations in BIN1 expression induce cardiac pathologies. We used a cardiomyocyte-specific PC1-silenced (PC1-KO) mouse model to explore the relevance of cardiomyocyte PC1 in the development of heart failure (HF), considering reduced BIN1 expression induced T-tubule remodeling as a potential mechanism. PC1-KO mice exhibited an impairment of cardiac function, as measured by echocardiography, but no signs of HF until 7-9 months of age. Of the PC1-KO mice, 43% died suddenly at 7 months of age, and 100% died after 9 months with dilated cardiomyopathy. Total BIN1 mRNA, protein levels, and its localization in plasma membrane-enriched fractions decreased in PC1-KO mice. Moreover, the BIN1 + 13 isoform decreased while the BIN1 + 13 + 17 isoform was overexpressed in mice without signs of HF. However, BIN1 + 13 + 17 overexpression was not observed in mice with HF. T-tubule remodeling and BIN1 score measured in plasma samples were associated with decreased PC1-BIN1 expression and HF development. Our results show that decreased PC1 expression in cardiomyocytes induces dilated cardiomyopathy associated with diminished BIN1 expression and T-tubule remodeling. In conclusion, positive modulation of BIN1 expression by PC1 suggests a novel pathway that may be relevant to understanding the pathophysiological mechanisms leading to cardiomyopathy in ADPKD patients.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology

